CLANOTECH AB
Clanotech is active in ophthalmology. Clanotechโs development strategy spans from indications with orphan drug opportunities such as developing safe and target specific anti-scarring treatment in glaucoma surgery techniques to therapeutic areas with high commercial potential as wet Age Related Macular Degeneration, proliferative diabetic retinopathy, proliferative vitreoretinopathy, pterygium etc..
CLANOTECH AB
Industry:
Biotechnology Health Care
Address:
Solna, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.clanotech.se
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ASP.NET IIS IIS 10 Classic ASP
More informations about "Clanotech AB"
Clanotech AB - Crunchbase Company Profile & Funding
Clanotech AB is active in ophthalmology. Clanotech is active in ophthalmology. Clanotechโs development strategy spans from indications with orphan drug opportunities such as โฆSee details»
ClanoTech AB - Företagsinformation - allabolag.se
ClanoTech AB,556706-6658 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för ClanoTech AB. Sök ... Gratis Med allabolag.se konto Hämta Köp utan โฆSee details»
Clanotech Company Profile 2024: Valuation, Funding & Investors
Clanotech General Information Description. Developer of pharmaceuticals designed to treat cancer and age-related muscular degeneration. The company's pharmaceuticals are strategy โฆSee details»
ClanoTech AB - Drug pipelines, Patents, Clinical trials - Synapse
Explore ClanoTech AB with its drug pipeline, therapeutic area, technology platform, , Technology Platform:Small molecule drug, Drug:CLT-28643. ... www.clanotech.se. Last update 01 Nov โฆSee details»
Clanotech AB - VentureRadar
Clanotech is developing small molecules for alpha5beta1-integrin inhibition for treatment of diseases of the eye. ... Find out more about Clanotech AB, Cancer Therapeutics and โฆSee details»
Clanotech AB Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Clanotech AB of Solna, Stockholm. Get the latest business insights from Dun & Bradstreet.See details»
Clanotech - Company Profile - Tracxn
Oct 23, 2024 Clanotech ranks 160th among 201 active competitors. 69 of its competitors are funded while 57 have exited. Overall, Clanotech and its competitors have raised over $5.46B โฆSee details»
Clanotech AB - Crunchbase
Clanotech AB is active in ophthalmology. Start Free Trial . Chrome ExtensionSee details»
CLANOTECH AB | TREA
Explore innovation relationships and map ideas to the unified knowledge graphSee details»
Clanotech, Solna, SE | Company Information
Infobel Sweden Industrial Production & Supplies Solna Clanotech. Categories. Industrial Production & Supplies (111) Other Companies & Services (6) Health & Medicine (4) Computer โฆSee details»
Clanotech AB - BioCentury Company Profiles - BCIQ
Apr 13, 2015 Clanotech AB - BioCentury Company Profiles for the biopharma industrySee details»
Clanotech - Products, Competitors, Financials, Employees, โฆ
Use the CB Insights Platform to explore Clanotech's full profile. Clanotech - Products, Competitors, Financials, Employees, Headquarters Locations Technology VendorsSee details»
Clanotech AB - Tech Stack, Apps, Patents & Trademarks
Organization. Clanotech AB . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 8. About. Clanotech AB is actively โฆSee details»
Clanotech granted Orphan Drug Designation by the U.S. FDA
Mar 27, 2015 For more information on the Orphan Drug Designation and Clanotech please visit: www.clanotech.se For further information, please contact: Jim Van heusden, CEO, Karolinska โฆSee details»
Clanotech AB Receives Orphan Drug Designation In The U.S.
Mar 27, 2015 Clanotech is a Swedish biotech company active in ophthalmology. Clanotech development strategy spans from niche indications with orphan drug opportunities such as โฆSee details»
Karolinska Development's Clanotech receives EU drug designation
Oct 20, 2014 * Clanotech AB announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency for โฆSee details»
CLT-28643 - Drug Targets, Indications, Patents - Synapse - Patsnap
Purpose To evaluate the therapeutic potential of the small molecule integrin ฮฑ5ฮฒ1 inhibitor, CLT-28643, to improve the filtering surgery outcome in a mouse model. Different dose regimens โฆSee details»
Clanotech Receives Orphan Drug Designation in the U.S.
Mar 28, 2015 Clanotech is now preparing for a phase I/II trial with CLT-28643โ, said Patrizia Caldirola, CEO, Clanotech. Clanotechโs lead compound, an ฮฑ5ฮฒ1-integrin antagonist, has anti โฆSee details»
Clanotech Drug Gets FDA Orphan Label - NLS - Nordic Life Science
Mar 30, 2015 Clanotech ABโs candidate drug CLT-28643 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for prevention of scarring after glaucoma โฆSee details»
CLT 28643 - AdisInsight - Springer
Aug 28, 2021 CLT 28643 is an alpha-5-beta-1 (ฮฑ5ฮฒ1) integrin inhibitor, being developed by Clanotech for the treatment of eye disorders to treat scarring after glaucoma CLT 28643 Next โฆSee details»